Integra Lifesciences Updates Investor Presentation Amid Refinancing Plans
TipRanks (Tue, 8-Sep 6:57 AM ET)
Globe Newswire (Fri, 4-Sep 9:15 AM ET)
Integra LifeSciences Reports Second Quarter 2026 Financial Results
Globe Newswire (Wed, 29-Jul 6:00 AM ET)
Business Wire (Thu, 23-Jul 7:00 AM ET)
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
Globe Newswire (Thu, 16-Jul 8:00 AM ET)
PRNewswire (Thu, 9-Jul 8:17 AM ET)
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Globe Newswire (Thu, 2-Jul 8:30 AM ET)
Integra LifeSciences Announces Key Executive Appointments
Globe Newswire (Tue, 23-Jun 8:00 AM ET)
Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild Itself
Globe Newswire (Thu, 18-Jun 12:42 PM ET)
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
Globe Newswire (Tue, 16-Jun 10:30 AM ET)
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Integra Lifesciences Holdings trades on the NASDAQ stock market under the symbol IART.
As of September 9, 2026, IART stock price declined to $16.25 with 546,703 million shares trading.
IART has a beta of 1.74, meaning it tends to be more sensitive to market movements. IART has a correlation of 0.12 to the broad based SPY ETF.
IART has a market cap of $1.26 billion. This is considered a Small Cap stock.
Last quarter Integra Lifesciences Holdings reported $419 million in Revenue and $.56 earnings per share. This beat revenue expectation by $746,680 and exceeded earnings estimates by $.08.
In the last 3 years, IART traded as high as $45.42 and as low as $8.70.
The top ETF exchange traded funds that IART belongs to (by Net Assets): VTI, VB, VBR, VXF, SPSM.
IART has underperformed the market in the last year with a price return of +3.6% while the SPY ETF gained +18.7%. IART has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.1% and -3.2%, respectively, while the SPY returned +3.4% and -0.5%, respectively.
IART support price is $15.82 and resistance is $16.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IART shares will trade within this expected range on the day.